A federal class action filed in Delaware in November 2025 puts a number on something the research channel has argued informally for two years: that the tirzepatide tablets and dissolving strips sold through telehealth storefronts have no mechanism for getting the molecule into the bloodstream. The complaint in Day v. OpenLoop Health Inc. (D. Del., No. 1:25-cv-01418) calls the product "snake oil" and alleges the named plaintiff paid $279.99 for a month's supply of a pill that, on the filing's account, could not have worked at any dose.
The case has been quiet since filing — the defendants moved to dismiss, the docket shows routine activity as recently as August 26, 2026, and no judge has ruled on anything. What makes it worth reading is not the litigation outcome. It is that the complaint assembles, in one place, the pharmacology of why oral peptide delivery is hard, sourced to FDA review documents and to the defendants' own competitors. That material is directly relevant to anyone comparing delivery formats for tirzepatide, and it does not appear anywhere else in a single document.
Research-context information only. This article reports on a publicly filed civil complaint and on published coverage of it. A complaint states one party's allegations and is not a finding by any court; the defendants have moved to dismiss and dispute the claims. Nothing here is medical or legal advice. Tirzepatide research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity or potency as sold. Consult a licensed physician for personal medical decisions.
What the filing alleges
The defendants are OpenLoop Health Inc. — a white-label operator that supplies clinician networks and back-end infrastructure to telehealth brands — along with Triad Rx Inc. and Triad Rx Buyer LLC, the compounding pharmacy side. The complaint describes a structure in which a large number of consumer-facing storefronts share the same underlying provider network and pharmacy, so that a buyer picking between what look like competing brands is often routed to the same fulfilment chain.
The named plaintiff's account is specific. He completed an online questionnaire covering medical history, height and weight; he never spoke to, video-conferenced with, or otherwise consulted a licensed clinician; his invoice carried one brand's name and logo but listed a different company's headquarters as the billing address. The supply period ran from roughly October 18 to November 15, 2025.
The complaint also reproduces public customer reviews that follow a repeating shape — buyers reporting no measurable result on the oral product across four to six weeks, then reporting an effect only after switching to an injectable. Those are consumer reviews quoted in a pleading, not trial data, and the filing presents them as such.
The causes of action are RICO, a set of state consumer-protection statutes, common-law fraud and unjust enrichment. The defendants' motion to dismiss argues the case "attempts to turn dissatisfaction with a prescription weight-loss treatment into a federal RICO action," that compounding is lawful, and that the plaintiff lacks RICO standing.
The absorption argument, in numbers
The pharmacology section is the part with durable value, and it runs on four figures.
Peptides are digested. Peptides are chains of amino acids, and the gut treats them the way it treats the protein in food — proteolytic enzymes break them down. The complaint cites the general finding that the gastrointestinal wall shows low permeability to peptides above roughly 1,000 Da. Tirzepatide is far above that line.
The one approved oral peptide GLP-1 needed a dedicated platform. The approved oral semaglutide tablet is co-formulated with sodium N-(8-[2-hydroxybenzoyl]amino) caprylate — SNAC — an absorption enhancer that acts locally in the stomach as a pH buffer, protects the molecule from enzymatic degradation, and temporarily raises gastric membrane permeability. It took years of dedicated formulation work.
Even with SNAC, absorption is marginal. Citing FDA's clinical pharmacology review for that product, the complaint states absolute bioavailability of roughly one percent, achieved only under tightly controlled conditions: empty stomach, small sip of water, no food or drink for at least thirty minutes afterward. That is the ceiling for a peptide GLP-1 taken by mouth with a purpose-built enhancer behind it.
Tirzepatide is the larger molecule. Semaglutide is approximately 4,114 Da; tirzepatide is approximately 4,813 Da. Semaglutide is a single-receptor GLP-1 agonist; tirzepatide is a dual GLP-1/GIP agonist with a different sequence, different structural modifications and a different receptor-binding profile. The complaint's position is that the SNAC platform was optimised for semaglutide's specific stability and solubility requirements and has not been shown to carry over.
The filing's supporting evidence for that last point is notable because of where it comes from. A large direct-to-consumer telehealth platform publishes a patient-education page stating plainly that oral tirzepatide "does not exist," that the molecule "is rapidly degraded by digestive enzymes within the gastrointestinal tract," and that "too little of it would remain in your system to be effective." That is a competitor in the same market disclosing the same conclusion. Separately, in Eli Lilly's own litigation against an oral-tirzepatide seller, the manufacturer's complaint states that no clinical study suggests tirzepatide taken orally is safe and effective, and that it does not sell any tirzepatide product in oral form.
The complaint's summary claim is that no compounded oral tirzepatide formulation has been shown in any peer-reviewed study to achieve measurable systemic bioavailability. That claim has not been tested in court.
What this means for anyone comparing formats
The practical read is narrow and worth stating without drama.
The delivery-route evidence is lopsided. Every published human efficacy trial for tirzepatide used subcutaneous injection. There is no equivalent body of data for tablets, orally disintegrating tablets or sublingual troches — the complaint alleges there is none at all. Someone comparing formats is not choosing between two evidenced routes at different price points; on the record as it currently stands, one route has the trial data and the other has marketing.
Price comparisons across formats are not like-for-like. A $279.99 monthly oral programme and a research-channel vial priced per milligram are not competing on the same axis, because the numerator differs. Cost per milligram only means something once the milligrams reach circulation. The tirzepatide buying guide tracks per-milligram pricing across vendors in the research supply channel, where the material ships as lyophilised powder intended for reconstitution — the same route the trials used.
The routing question matters more than the brand name. The complaint's core structural allegation is that many separate-looking storefronts run through one provider network and one pharmacy. Whatever the court makes of the legal claims, that is a checkable fact pattern: whose name appears on the invoice versus the billing address, and which clinician network the intake form actually reaches.
Reconstitution is the step where format is decided. Research-channel tirzepatide, sold labeled for research use only, arrives as powder; trial and community protocols describe reconstitution with sterile diluent for subcutaneous use. Our tirzepatide reconstitution guide reports that arithmetic, and the dosing guide reports the titration schedules used in the published trials.
